BioLineRx Interest Income Over Time

BLRX Stock  USD 3.35  0.03  0.90%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out BioLineRx Performance and BioLineRx Correlation.
For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.
  
Interest Income is likely to rise to about 2.4 M in 2025, whereas Net Interest Income is likely to drop (153.1 K) in 2025.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioLineRx. If investors know BioLineRx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioLineRx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(12.00)
Revenue Per Share
11.4
Return On Assets
(0.33)
Return On Equity
(1.84)
The market value of BioLineRx is measured differently than its book value, which is the value of BioLineRx that is recorded on the company's balance sheet. Investors also form their own opinion of BioLineRx's value that differs from its market value or its book value, called intrinsic value, which is BioLineRx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioLineRx's market value can be influenced by many factors that don't directly affect BioLineRx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioLineRx's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioLineRx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioLineRx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Interest Income Analysis

Compare BioLineRx and related stocks such as Ardelyx, Lexicon Pharmaceuticals, and Seres Therapeutics Interest Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
2010201120122013201420152016201720182019202020212022202320242025
ARDX127.7 M127.7 M127.7 M127.7 M127.7 M127.7 M127.7 M127.7 M127.7 M5.8 M5.8 M5.8 M5.8 M5.8 M5.2 M4.9 M
LXRX6.7 M6.7 M6.7 M6.7 M6.7 M6.7 M2.3 MM3.5 M3.4 M2.8 M134 K1.6 M6.2 M5.6 M5.9 M
MCRB631 K631 K631 K631 K631 K631 K2.2 M1.6 M1.2 MM946 K2.9 M3.1 M6.7 M7.8 M8.1 M
IBRX5.2 M5.2 M5.2 M5.2 M5.2 M5.2 M5.2 M3.6 M1.9 M1.6 M1.2 M836 K2.7 MM1.8 M1.9 M
XFOR472 K472 K472 K472 K472 K472 K1.1 M214 K809 K1.2 M273 K10 K219 K3.3 M3.8 MM
MREO25.7 K25.7 K25.7 K25.7 K25.7 K25.7 K374.9 K826.9 K306.8 K183 KK1000696 K2.1 M2.5 M2.6 M
INZY284 K284 K284 K284 K284 K284 K284 K284 K284 K1.1 M370 K211 K1.9 M4.1 M4.7 M4.9 M
TERN332 K332 K332 K332 K332 K332 K332 K332 K332 K1.2 M55 K170 K2.1 M12.9 M14.8 M15.6 M
LPTX128 K128 K128 K128 K128 K128 KK170 K447 K313 K93 KK925 K3.6 M4.2 M4.4 M
VRCAKKKKKKKK1.2 M1.9 M521 K123 K476 K2.2 M2.6 M2.7 M
VRNA35.5 K35.5 K35.5 K35.5 K35.5 K35.5 K86.5 K345 K861 K754 K121 K14 K2.8 M11.3 M13 M13.7 M
PLX589 K589 K589 K589 K589 K589 K589 K188 K536 K407 K438 K401 K1.1 M1.3 M1.5 M1.6 M
CDTX632 K632 K632 K632 K632 K632 K632 K632 K632 K632 K191 K191 K191 KM2.3 M2.4 M
FBIO3.4 M3.4 M3.4 M3.4 M3.4 M3.4 M298 K819 K1.1 M2.6 M1.5 M649 K1.4 MM3.4 M1.8 M
MBIO16 K16 K16 K16 K16 K16 K16 K505 K569 K1.3 M708 K368 K689 K1.1 M1.2 M710.6 K
APTO1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M78.1 K68 K283 K574 K522 K94 K788 K1.4 M1.6 M1.7 M
JavaScript chart by amCharts 3.21.15Macroaxis Charts20122014201620182020202220241K10K100K1M10M100M
JavaScript chart by amCharts 3.21.15Ardelyxtotal: 1.2BLexicon Pharmaceuticalstotal: 73.6MSeres Therapeuticstotal: 39.3MImmunitybiototal: 54.1MX4 Pharmaceuticalstotal: 17.9MMereo BioPharma Grouptotal: 9.7MInozyme Pharmatotal: 19.8MTerns Pharmaceuticalstotal: 49.8MLeap Therapeuticstotal: 14.8MVerrica Pharmaceuticalstotal: 11.7MVerona Pharma PLCtotal: 43.3MProtalix Biotherapeuticstotal: 11.6MCidara Therapeuticstotal: 13.6MFortress Biotechtotal: 36.7MMustang Biototal: 7.2MAptose Biosciencestotal: 14M

BioLineRx and related stocks such as Ardelyx, Lexicon Pharmaceuticals, and Seres Therapeutics Interest Income description

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

My Equities

My Current Equities and Potential Positions

BioLineRx
BLRX
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationIsrael
ExchangeNASDAQ Exchange
USD 3.35
100%

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.